Physician profile
Ivan Pena Sing
NPI 1225021611
$9,290.86
in general payments reported to CMS, 2019-2025
32 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $415 · 2021: $994 · 2022: $1,211 · 2023: $754 · 2024: $883 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094 · Travel and Lodging: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,093.98 |
| Travel and Lodging | $1,172.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,891.37 | 2024-2025 | Indigo System |
| Baylis Medical Company INC | $1,082.28 | 2019 | |
| Teleflex LLC | $877.76 | 2019-2025 | Trapliner, Orsiro Mission, Guideliner |
| Abbott Laboratories | $870.12 | 2020-2025 | Nc Trek Neo, Xience Skypoint, Pressurewire |
| Medtronic, INC. | $752.52 | 2021-2025 | Simulus, Cobalt Dr Mri Surescan, Selectsecure |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $633.87 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $630.31 | 2019-2025 | Avvigo Guidance System, General - Molecular Intervention, Ekosonic |
| Medtronic Vascular, INC. | $347.96 | 2019 | |
| Abiomed | $332.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $280.98 | 2020-2023 | Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.12 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $185.84 | 2020-2023 | Camzyos, Eliquis |
| Biotronik INC. | $167.88 | 2022 | |
| Astellas Pharma US INC | $153.98 | 2019 | |
| Chiesi USA, INC. | $129.21 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $124.83 | 2019-2022 | |
| Amgen INC. | $92.59 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $72.20 | 2021-2023 | |
| Bard Peripheral Vascular, INC. | $66.20 | 2019-2020 | |
| Pfizer INC. | $63.21 | 2021-2023 | |
| Edwards Lifesciences Corporation | $42.22 | 2024 | Sapien 3 Ultra Resilia |
| Terumo Medical Corporation | $29.32 | 2019-2020 | |
| Stryker Corporation | $29.30 | 2025 | Flowtriever |
| Irhythm Technologies, INC. | $24.39 | 2021 | |
| Glaxosmithkline, LLC. | $24.21 | 2024 | Nucala |
| Cardinal Health 200 LLC | $21.20 | 2021 | |
| Ge Healthcare | $19.62 | 2021 | |
| Elutia, INC. | $17.27 | 2021 | |
| Cardiovascular Systems INC. | $16.92 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.15 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $13.55 | 2022 | |
| Lantheus Medical Imaging, INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Pena Sing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.